17,261 trials
Neonatal Seizures
Primary: Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg) — 15; 24 Participants — p=<0.001
Sclerosing Cholangitis
Primary: Adverse Event Frequency — 8 Participants
Nonalcoholic Fatty Liver Disease · HIV
Primary: Efficacy of Aramchol 600 mg vs. Placebo in Improving Hepatic Steatosis Assessed by Magnetic Resonance Imaging in Patients With HIV-associated NAFLD — 13.7; 11.1…
Congenital Heart Disease · Heart Failure · Endomyocardial Fibrosis
Primary: Extracellular Volume Fraction — 30.1; 25.3 percentage of myocardium
Obesity · Weight Loss · Overweight and Obesity
Primary: Safety: The Incidence of Treatment-related Adverse Events [AEs] — 0; 0; 0; 0 participants
Prostate Cancer
Primary: Maximum Tolerated Dose (MTD) of Temsirolimus (Phase I) — 25 mg
Obese · Insulin Resistance · Metabolic Syndrome
Primary: Circulating LPS — 2.44; 1.86; 13.66; 10.00 EU/mL — p=>0.05
Malignant Glioma · Glioblastoma · Brain Cancer
Primary: Number of Treatment Related Adverse Events — 0; 0; 0; 0 adverse events
Mycobacterium Infections, Nontuberculous
Primary: Change in Semi-Quantitative Mycobacterial Culture Results From Baseline to Day 84. — 5; 5; 1; 1 Participants — p=0.072
Pulmonary Hypertension
Primary: Change in Right Ventricular Mass From Baseline — 3.9; -5.2 grams — p=0.028
Graft-versus-host Disease (GVHD)
Primary: Overall Response Rate (ORR) at Day 28 — 19; 7; 13 Participants
Pain · Cesarean Section
Primary: Post Operative Fentanyl PCA Consumption — 300; 446 µg
Aphasia
Primary: The Philadelphia Naming Test (PNT) Plus the Naming 80 (a Portion of the Trained Items). — 13.9; 8.2 PNT and Naming 80 score
Adenocarcinoma of the Prostate
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 2; 6; 3 Participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline to Week 26 in Hemoglobin A1c (HbA1c) Bayesian Dose Response — -0.06; -1.06; -1.73; -1.89 Percentage of HbA1c